Skip to main content
SP5007,769.06-0.21%DOW53,518.83-0.40%NASDAQ26,713.00-0.06%BTC$64,067.00+1.39%ETH$1,905.81+0.95%GOLD$4,481.80+1.00%OIL$82.77+0.45%
Smart Investors Daily
Sign InSign Up Free
CW

NASDAQ · CWBR

CohBar, Inc.

Healthcare · Biotechnology

$0.41

Up+$0.00 (+0.00%)

Updated Aug 17, 2026, 4:42 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.19M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
— – —
Volume
172
Avg. volume
3.04K

Price performance

CWBR price history

1M range · 0 trading sessions · Daily adjusted prices

CWBR does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CWBR news

The latest Smart Investors Daily articles mentioning CWBR.

Stock researchCompany · Overview

CWBR research

Overview

Company profile and research snapshot.

Company profile

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CWBR recent ratings
DateFirmRatingTarget
Aug 11, 2021WBB SecuritiesBuy—
Apr 23, 2021Maxim GroupBuy—
Mar 15, 2021Aegis CapitalBuy—
Dec 17, 2020Chardan CapitalBuy—
Oct 15, 2020WBB SecuritiesSpeculative Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Sep 22, 2023

Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Gainers GSE Systems, Inc. (NASDAQ: GVP) shares rose 32.4% to $0.4090 in pre-market trading after falling over 3% on Thursday. Roadzen (NASDAQ: RDZN) shares rose 23.4% to $8.11 in pre-market trading after falling more than 40% on Thursday. FLJ Group Limited (NASDAQ: FLJ) shares gained 20.3% to $0.3669 in pre-market trading. Blue Star Foods Corp. (NASDAQ: BSFC) shares rose 17.1% to $0.37 in pre-market trading. Blue Star Foods recently announced closing of $5 million public offering. Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 17% to $0.1199 in pre-market trading after falling 8% on Thursday. The company recently agreed to divest AVTX-800 series. Blue Water Biotech, Inc. (NASDAQ: BWV) rose 15.7% to $0.6494 in pre-market trading. Maxim Group recently downgraded Blue Water Biotech from Buy to Hold. Infobird Co., Ltd (NASDAQ: IFBD) shares surged 13% to $0.15 in pre-market trading. Infobird recently announced receipt of delinquency notification letter from Nasdaq. Solowin Holdings (NASDAQ:

GlobeNewswire Inc. · Aug 14, 2023

CohBar Reports Second Quarter 2023 Financial Results

MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023.

GlobeNewswire Inc. · May 30, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By